Home > Boards > US OTC > Delisted > Intellicell Biosciences, Inc. (fka SVFC)

Updated SVFC & CYTX-Compare & Contrast…

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (18) | Next 10 | Previous | Next
stervc Member Profile
Member Level 
Followed By 4,736
Posts 23,288
Boards Moderated 18
Alias Born 09/20/00
160x600 placeholder
stervc Member Level  Thursday, 01/23/14 04:01:38 AM
Re: None
Post # of 91005 
Updated SVFC & CYTX-Compare & Contrast…

Below is ”Compare & Contrast” analyst that I put together to help investors to see the potential undervaluation that exists here with SVFC compared to a stock that signed a $531 Million deal which trades on the NASDAQ under the ticker of CYTX:
Quote:

Cytori Signs $531 Million Deal With New Australian Company
http://ir.cytori.com/investor-relations/News/news-details/2013/Cytori-Licenses-Asia-Pacific-Cardiovascular-Renal--Diabetes-Markets-to-Lorem-Vascular-for-up-to-531-Million/default.aspx



Observe below a study from Merck that confirmed that the SVFC (IntelliCell) stem cell process was 10 times greater than Cytori which trades on the NASDAQ under the ticker of CYTX at $2.60+ per share:
Quote:

http://www.forbes.com/sites/genemarcial/2011/08/28/human-bodys-fat-seen-as-best-source-of-stem-cells-for-regenerative-therapies/
A study of IntelliCell’s technology by Millipore, a division of Merck AG of Germany, confirmed that it produced an average of 10 times the number of SVF cells containing adult adipose stem cells from less than which the company believes is used by any of its present competition that use enzymes in their process. The study also showed that the SVF cells produced by IntelliCell contain all of the viable cells that are manufactured by competing technologies that use enzymes, such as Cytori.



Bottom line, my point is that if CYTX is trading in the $3.00+ per share range on the NASDAQ, then SVFC (IntelliCell) should not trading here at .0049 per share, but definitely somewhere much higher, especially considering that CYTX signed a $531 Million deal because of its technology while SVFC has a technology that has been proven to be 10 times superior than the technology that CYTX has.

Now let’s compare & contrast SVFC with CYTX

http://www.cytori.com/Home.aspx


http://www.intellicellbiosciences.com/index.html


CYTX = $3.09 per share
SVFC = .0049 per share


CYTX Outstanding Shares (OS) = 67,270,000 shares
(Source Yahoo Finance)
http://finance.yahoo.com/q/ks?s=CYTX+Key+Statistics
SVFC Outstanding Shares (OS) = 600,000,000 shares
(Source: Only a Current Worst Case Scenario Guess)

CYTX Market Cap = $3.09 x 67,270,000 = $207,864,300 as of Jan 22, 2014
SVFC Market Cap = .0049 x 600,000,000 = $2,940,000 as of Jan 22, 2014

Just by considering the above Market Cap Analysis for both SVFC and CYTXSVFC is 70.7 times cheaper or smaller than where CYTX exists, but yet the SVFC stem cell process is 10 times better. This means that it could be justified for SVFC to be trading 70.7 times higher than its current price of .0049 per share. That would equate to… .346 per share for a value of where SVFC could fundamentally exist to trade; conservatively speaking. Use the Substitution Property to substitute any variable above that might change at any particular time.

Let’s further analyze why SVFC has a better stem cell process than CYTX:
Quote:

http://www.thelifesciencesreport.com/pub/na/the-stem-cell-revolution-can-jump-start-your-portfolio-jason-kolbert
…The IntelliCell process, branded IntelliSonics, is similar to the Cytori process in that they both use lipoaspirate. But the IntelliCell process produces a different cellular population because, with its sonification (ultrasound) process, the blood components are not washed out. The stromal vascular fraction of IntelliCell contains the hematopoietic cells. The final product is quality-controlled, checked for any contamination and cell viability is measured. …



Something else that was key to note was that SVFC mentioned that they have completed the preclinical protocols in anticipation expects to begin a clinical trial for osteoarthritis of the knee under an FDA investigational new drug application in mid-2013. An email from the company was recently posted confirming that news is due any day now. This very well could be one of the few of the long awaited PRs expected to be released.

Also important to note is that SVFC provides product today to ReGen Medical while at the same time is building a fantastic database of patient experience that will be used to focus on clinical applications:

http://regenmedicalpc.com/cellular-therapy.php


http://www.victordermatologyandrejuvenation.com/


http://www.stevenvictormd.com/


Again… Bottom line, my point is that if CYTX is trading in the $3.09 per share on the NASDAQ, then SVFC (IntelliCell) should not trading here at .0049 per share, but definitely somewhere much higher, especially considering that CYTX signed a $531 Million deal because of its technology while SVFC has a technology that has been proven to be 10 times superior than the technology that CYTX has.

v/r
Sterling


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (18) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences